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ABSTRACT
Objective: A stability indicating chiral high performance liquid chromatographic (HPLC) method was developed and validated for the separated (S) 
and (R) pioglitazone in raw material and its determination in the presence of degradation products formed during forced degradation studies.










Pioglitazone is chemically known as (RS)-5-(4-[2-(5-ethylpyridin 
2yl)ethoxy]benzyl)thiazolidine-2,4-dione.  Pioglitazone  is  the 
thiazolidinedione-ring with the chiral center [1]. Glitazones are potent 
insulin sensitizers. In recent years, direct resolution of enantiomers 
without prior derivatization has come into use as alternative 
procedures to indirect methods [2-6]. These methods involve the use of 
chiral stationary phases that form transient diastereomeric complexes 
with solute enantiomers. Investigation of the single enantiomers in a 
racemic mixture may be valuable  in order  to  investigate whether  the 
single enantiomers demonstrate the difference in pharmacological 
effect and/or effect ratio than the other. However, in order to perform 
the necessary investigations for making decisions regarding this, it is 
required to test the enantiomers separately. So, the pure enantiomers 
should either be synthesized (if possible) or purified from the racemic 
mixture using preparative separation methods. The aim of the current 
study is to demonstrate that it is possible to separate enantiomers from 
a racemic mixture of pioglitazone with respect to further investigations 
on these important potent insulin sensitizers, which in turn leads to 
a possible better treatment of diabetes. Development of a better and 
safer drug product may be considered if one of the enantiomers has a 
significantly better effect than the other. Literature survey revealed that 
only high performance liquid chromatographic (HPLC) methods for 
its determination in pharmaceuticals and in human serum have been 
reported [7-10].
The stability-indicating assay methods  (SIAMS) are employed  for  the 
analysis of stability samples in the pharmaceutical industry. With the 
advent of International Conference on Harmonization (ICH) guidelines, 
the  requirement  of  establishing  SIAM  has  become  mandated  [11]. 
The guidelines explicitly require the conduct of forced decomposition 
studies under a variety of conditions, such as pH, light, oxidation, dry 
heat,  etc.  and separation of  the drug  from degradation products. The 
developed method is expected to allow analysis of individual degradation 
products. The ICH guideline Q1A (R2) [12] emphasizes that the testing 
of those features, which are susceptible to change during storage and 
are likely to influence quality, safety and efficacy of the drug, must be 
examined by  validated  stability  indicating  testing method. As per Q1 
(R2)  information on  the stability of  the drug substance  is an  integral 
part of the systematic approach to stability evaluation. Stress testing of 
the drug substance can help identify the likely degradation products, 
which can in turn help establish the degradation pathways, the intrinsic 
stability of the molecule, and validate the stability indicating power of 
the developed analytical procedures. The nature of  the  stress  testing 
will depend on the individual drug substance and the type of drug 
product involved.
From the literature review, it is observed that no stability indicating 
assay method for the determination of pioglitazone enantiomers was 
available keeping in the view of the susceptibility of pioglitazone 
enantiomers under a variety of conditions. It was felt that an (SIAMS) 
that separates the drug enantiomers from their degradation products 




fine chemicals and S.D. fine chemicals. Reference standards of 
Pioglitazone enantiomers were procured from Sigma-Aldrich limited, 
Mumbai,  India.  Working  standard  of  pioglitazone  RS  (99.37%)  was 
obtained as gift  sample  from Micro Labs Limited, Hosur, Tamil Nadu, 
India. Commercially available tablets Pioglitazone were purchased 
commercially from the local market, Ooty, Tamil Nadu, India.
Apparatus and instrument conditions
Chromatographic separation and quantitative determination were 
performed using a HPLC containing a Shimadzu gradient pump (LC-20 
AD  solvent  delivery  system),  an  ultraviolet  detector  (Shimadzu).  The 
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Preparation of standard solution
The stock solutions containing 1 mg/ml of R and S form of pioglitazone 
were  prepared  in  methanol.  These  stock  solutions  were  stored  in 
light-resistant  containers.  Aliquots  of  R-pioglitazone  (5-15  µg/ml) 
and  S-pioglitazone  (4-14  µg/ml) were  prepared  in  the mobile  phase 
for analysis.
Preparation of sample solution
Twenty  tablets were weighed, to determine the average weight and 
finely  powdered.  The powder  equivalent  to  5 mg of R  and  S  form of 




R and S enantiomers of pioglitazone from one formulation (Pepar tablet 
containing 15 mg of pioglitazone) were extracted in the mobile phase. 
The  standard  and  sample  solutions were  analyzed  by  the  optimized 
chromatographic conditions, the chromatograms were recorded.
Forced degradation study of pioglitazone
In order to establish whether the analytical method and the assay 
were indicating stability, pure active pharmaceutical ingredient (API) 
of both pioglitazone enantiomers was forced under various stress 
conditions to conduct degradation studies. As the two enantiomers are 
freely soluble and stable in methanol, it was used as a co-solvent in all 
the forced degradation studies. All solution used in forced degradation 
studies, were prepared by dissolving API in small volume of methanol 
and  later  diluted  with  aqueous  hydrogen  peroxide,  distilled  water, 
aqueous hydrochloric  acid or  aqueous  sodium hydroxide  to achieve a 
concentration of 100 mcg/ml of pioglitazone. Photodegradation studies 
were performed  in methanol. The  solutions were exposed  to  sunlight 
during the day time for 4 days. The resultant solutions were analyzed 
every day, control samples which were protected from light with 
aluminum foil were also placed in the daylight concurrently, and studied 
for any degradation with the optimized chromatographic condition.
RESULTS AND DISCUSSION
Optimized of chromatographic conditions
A solvent  combination of n-hexane: N-propyl  alcohol  (80:20, % V/V) 
on a ACI Cellu 1 (150 mm × 4.6 mm i.d., 5 μ) as stationary phase gave 
satisfactory separation of R and S pioglitazone and their degradation 
products  formed  under  various  stress  conditions.  The  detection was 
carried out at 233 nm with a flow rate of 1.0 ml/minute. The retention 
times  of  pioglitazone  R  and  S were  observed  to  be  3.6 minutes  and 
4.6 minutes, respectively (Figs. 1 and 2).
The HPLC studies of samples obtained on stress testing of pioglitazone 
enantiomers under different conditions suggested the following 








was degraded as compared  to  the standard solution of  the drug. The 
drug enantiomers were completely degraded when utilized 30% H2O2 
but  falling  by  8%  by  using  3%  H2O2  through  24  hrs  (Fig.  3).  Under 
neutral conditions R and S pioglitazone enantiomers were found to be 
stable up to 24 hrs. Moreover very slight degradation was observed on 
exposure of solution and solid drug powder to sunlight. Temperature 
stress studies R and S pioglitazone enantiomers were found to be stable 
at 24 hrs.
The  calibration  curves  of  R-pioglitazone  and  S-pioglitazone  were 
linear in the range of 5-15 μg/ml and 4-14 μg/ml respectively. Linear 
Fig. 2: Typical high performance liquid chromatographic 
chromatogram of pioglitazone sample I solution
Fig. 3: Typical high performance liquid chromatographic 
chromatogram of oxidative degradation sample of pioglitazone 
(R band S) with 0.1N HCl at 24 hrs
Fig. 1: Typical high performance liquid chromatographic 
chromatogram of pioglitazone standard solution
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regression equation and correlation coefficient are shown in Table 2. 
The  precision  of  the  method  was  demonstrated  by  reproducibility 
studies.  The  mean,  standard  deviation  and  %  relative  standard 
deviation  (RSD)  were  calculated.  The  %  RSD  values  were  found  to 
be  <2%  revealed  that,  the method was  precise.  The  accuracy  of  the 
optimized methods was determined by absolute recovery experiments. 
An analysis of the results showed that the percentage recovery values 
were close to 100 % thus establishing that the developed method is 
Fig. 5: Typical high performance liquid chromatographic 
chromatogram of oxidative degradation sample of pioglitazone 
(R and S) with 3% H2O2 at 24 hrs
Fig. 4: Typical high performance liquid chromatographic 
chromatogram of oxidative degradation sample of pioglitazone 
(R and S) with 0.1N NaOH at 24 hrs
Table 1: Stress degradation studies of pioglitazone RS












R S R S R S R S R S
1N HCl 1N NaOH 30% H2O2 Powder form
1 0 0 0 0 0 0 0
2 2 28.65 23.16 36.56 38.86 25.53 23.76 24 hrs
0.1 N HCl 0.1N NaOH 3% H2O2 0.21 0.24
1 0 0 0 0 0 0 0 0 0
2 2 0.43 1.93 19.67 20.44 0.17 0.27 0.02 0.99
3 4 0.53 1.98 20.26 20.62 0.19 0.47 0.39 1.02 Solution form
4 6 1.78 1.96 20.27 23.63 0.57 0.50 1.75 3.70 24 hrs
5 8 2.44 2.13 21.41 24.26 0.64 0.52 2.02 5.78 0.16 0.14
6 12 2.76 2.61 25.02 25.02 0.66 0.57 7.25 7.18
7 24 3.87 3.22 25.20 25.82 0.75 0.62 7.86 7.51
accurate and reliable (Table  3).  Detection  limits  and  quantification 
limits of R-pioglitazone and S-pioglitazone were found to be 
1.4 μg/ml and 4.26 μg/ml respectively (Table 1). No marked changes 
in the chromatogram occurred on changing the instrument; operator 
and chromatographic conditions indicated that the developed method 
was  rugged  and  robust.  The  column  efficiency,  resolution  and  peak 
asymmetry were calculated for the standard solutions. Signal to noise 




of the system for the analysis of pioglitazone enantiomers in a 
pharmaceutical formulation. Additionally, the developed HPLC method 
was also applied for the estimation of pioglitazone in pharmaceutical 
formulations.
Method validation
The  normal  phase  HPLC  method  was  validated  according  to  ICH 
guidelines.  The  linearity  of  R  and  S  pioglitazone  were  studied  by 
preparing  and  assaying  a  series  calibration  standard  at  six  different 
concentrations within the range from 5 to 15 μg/ml of R-pioglitazone 
and  4-14  μg/ml  of  S-pioglitazone.  A  good  linear  relationship  was 
observed between the peak area ratios of R and S pioglitazone and the 
concentrations in the investigated concentration range.
The  specificity  of  the  method  was  ascertained  by  analyzing  the 
standards  and  the  samples.  The  peaks  of  R  and  S  pioglitazone  in 
samples were confirmed by comparing the retention time and spectra 
of  the  standards.  Six  injections  at  three  different  concentrations  of 
R-pioglitazone  (5,  10,  15  μg/ml)  and  S-pioglitazone  (4,  9,  14  μg/ml) 
enantiomers were made and analyzed to examine the precision of the 




at  three  levels,  namely,  80%,  100%,  and  120%  of  the  nominal 
Table 2: Linearity and range for S and R pioglitazone 
enantiomers by HPLC









1 5 326557 4 263294
2 7.5 489845 6.5 427865
3 10 653119 9 592431
4 12.5 816398 11.5 756990
5 15 979679 14 921537
HPLC: High performance liquid chromatographic
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concentration  of  pioglitazone,  during  degradation  studies.  Triplicate 
samples  were  prepared  for  each  recovery  level.  The  solutions  were 




was determined by making small changes in the chromatographic 
conditions such as flow rate, and mobile phase composition were 
deliberately varied and resolution between the two peaks is 
found >2.0  and % RSD of  all  the  compounds were within  the  limit 
and this illustrates the robustness of the method as stated in ICH 
guidelines.
CONCLUSION
A highly specific stability-indicating chiral HPLC assay method 
was developed for the quantification of pioglitazone enantiomers 
in  the  presence  of  their  degradation  products.  The  enantio-  the 
separation was carried out by the use of the cellulose-based chiral 
column. The  total  run  time  for  the developed method  is  10 minutes. 
The  method  provides  good  sensitivity  and  excellent  precision  and 
reproducibility.
Table 3: Results of analysis of drug products and recovery studies for S and R pioglitazone enantiomers by HPLC
Sample Label 
claim (mg)
Amount present (mg/tablet)±% RSD* % Label claim % Recovery±%RSD*
R and S R S R and S R S
I 15 15.11±0.25 8.34±0.39 6.75±0.45 100.70±0.93 55.66±0.67 45.03±0.64 100.04±0.92
II 15 15.22±0.52 8.47±0.76 6.74±0.65 101.48±0.47 56.50±0.98 44.97±0.18 98.40±0.51
III 30 30.45±0.44 16.88±0.89 13.56±0.84 101.51±0.34 56.29±0.63 45.21±0.32 97.14±0.96
IV 30 30.39±0.97 16.87±0.51 13.52±0.34 101.31±0.68 56.23±0.28 45.08±0.51 99.88±0.53
HPLC: High performance liquid chromatographic, RSD: Relative standard deviation
Table 4: System suitability studies for estimation of S and R 
pioglitazone enantiomers by HPLC
S. No Parameters R - pioglitazone S - pioglitazone




3 Correlation coefficient 0.996 0.996
4 Theoretical plate/meter 54082 54365
5 Resolution factor 1.85
6 Asymmetric factor 1.02 1.01
7 LOD (µg/ml) 1.4 1.4
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